| Literature DB >> 31108008 |
Raghavan Chinnadurai1, Augustine Rajakumar2, Andrew J Schneider1, Wade A Bushman1, Peiman Hematti1, Jacques Galipeau1.
Abstract
Potency assays for mesenchymal stromal cells (MSCs) need to be defined in advanced clinical trials. Here, we have developed an assay matrix approach that captures the signal transducer and activator of transcription (STAT) phosphorylation of MSCs upon stimulation with their combined secretome that arose with the interaction of activated peripheral blood mononuclear cells (PBMCs). Secretome of heat-inactivated (HI) MSCs cocultured with and without activated PBMCs was used as an internal reference. We have compared the short-term phosphorylation status of STAT1, STAT3, STAT4, STAT5, and STAT6 on MSCs derived from human bone marrow, adipose tissue, and umbilical cord using phosflow technology. Secretome of live MSCs cocultured with activated PBMCs downregulate STAT1 and STAT3 phosphorylation on MSCs, whereas the secretome of HI-MSCs or PBMCs do not. Thus, investigation of the combined secretome of MSC and PBMC interaction on MSCs determine the potency of MSCs as the generator and sensor of the secretome. Bone marrow, adipose, and umbilical cord MSCs are comparable in modulating STAT1 and STAT3 responses. Measurements of STAT1 and STAT3 phosphorylation on MSCs as responder cells correlate and predict allogeneic T-cell suppression. Our comparative phosphomatrix approach between live and reference HI-MSCs defines the potency of MSCs as both stimulators and responders as part of a robust platform for predictive potency analysis. Stem Cells 2019;37:1119-1125. © AlphaMed Press 2019.Entities:
Keywords: Assay matrix; Immune suppression; Mesenchymal stromal cells; Phosflow; Phospho-STAT; Potency analysis
Mesh:
Substances:
Year: 2019 PMID: 31108008 PMCID: PMC6729138 DOI: 10.1002/stem.3035
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277